With majority control of the Senate and House split between Democrats and Republicans, Congress will likely shift focus to reducing drug prices in 2019. Both parties want to address the issue, and it is also a major agenda item for President Donald Trump.
Still, drug stocks went up after the midterms, according to Bloomberg. Analyst Andrea Harris told Bloomberg the disruptive policy change on pharmaceutical companies is unlikely.
Read the full report here.
More articles on leadership and management:
If employees aren’t speaking up, take a look at company culture
Corner Office: Cook County Health and Hospitals System CEO Dr. John Jay Shannon on the importance of strong teams
‘We’re working on healing’: UPMC physician discusses synagogue shooting response
